SI BONE INC (SIBN)
Health Care · Orthopedic implants and devices · NASDAQ
SI-BONE is a medical device company providing minimally invasive surgical solutions to treat conditions of the sacroiliac joint and spinopelvic anatomy.
What SI BONE INC does
SI-BONE designs, manufactures, and commercializes implantable devices and surgical instruments for sacroiliac joint fusion procedures. The company's portfolio addresses disorders of the spinopelvic anatomy, with the sacroiliac joint being a primary focus. SI-BONE markets its products to orthopedic surgeons and neurosurgeons, working to establish physician adoption and secure reimbursement from third-party payors. The company is pursuing clinical development and regulatory approvals across multiple jurisdictions including the FDA and European regulatory bodies.
Themes: minimally invasive surgery, orthopedic implants, spinopelvic health, musculoskeletal disorders
Fundamentals
- Price$19.96 as of 2026-08-21 close
- Market cap$895M as of 2026-08-21
- 1-year return+27.6% 2025-08-21 close $15.64 → 2026-08-21 close $19.96
- P/En/a negative earnings
- Net margin-6.8% as of 2026-08-24
- Gross margin+79.5% as of 2026-08-24
- ROE-8.2% as of 2026-08-24
- Debt / equity0.20 as of 2026-08-24
- Revenue growth (YoY)+15.3% as of 2026-08-24
- Revenue CAGR (3y)+23.6% SEC XBRL
- Beta0.68 as of 2026-08-24
- Last reported earnings2026-08-03 SEC EDGAR Form 8-K (Item 2.02)
How SIBN compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How SI BONE INC looks technically
SI BONE INC (SIBN) is trading 22.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 18 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 33, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 68, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day high, its first since 2026-01-09, pushing above its recent trading range. Trading volume is running unusually high — about 2.7× its 30-day average, a sign of heightened interest.
Trend
8
| Distance from the 200-day | it is trading 22.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +22.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $17.44 | $17.44 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $16.26 | $16.26 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 17 calendar days ago — the swings before that are what the structure reading is measured on | 17 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 18.165. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 18 trading days ago — a "golden cross", a bullish long-term signal | 18 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 33, with buyers in control | 32.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 68, neither overbought (above 70) nor oversold (below 30) | 67.6 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($17.65 to $20.05) — its "stochastic" reading is 96 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 96.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 17 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $21.89 | $21.89 |
|---|---|---|
| From the 52-week high | it is 8.8% below its 52-week high (its highest price of the past year) | -8.8% |
| Above the 52-week low | it is 73.9% above its 52-week low (its lowest price of the past year) | +73.9% |
| Below the 52-week high | it is 8.8% below its highest point of the past year | 8.8% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-01-09, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, its first since 2026-01-09, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $37.21 (set on 2021-05-04) | $37.21 |
| Given back of the 52-week move | over the past year its closes ranged ($11.61 to $21.40), and it has recovered almost all of its fall from last year’s high — 85% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $17.66 to $17.97. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 85.3% |
| From the all-time high | it is 46.4% below its all-time high | -46.4% |
| Nearest price level | it is sitting right on a resistance level at $19.98 — a price it turned at three times since 2025-05-16, most recently on 2025-12-08. Since 2024-08-21 it has 12 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.1% |
| All-time low | its lowest closing price on record is $7.20 (set on 2020-03-18) | $7.20 |
| Above the all-time low | it is 177.2% above its all-time low | +177.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 71% of it) | 29th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.7085 between its high and its low — about 3.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.7085 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $17.24 and $20.02 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $17.24 – $18.63 – $20.02 |
| Typical daily range (% of price) | its price moves about 3.6% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.5% |
| Stretch from the 200-day average | it is trading 5.2 daily ranges above its 200-day average price (22.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 2.7× its 30-day average, a sign of heightened interest | 2.70× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | today it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | today |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | -0.1% |
|---|---|---|
| Open gap | it gapped 3.9% above the previous close 18 sessions ago and has not traded back through the level it left behind at 17.05 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.9% |
| Gap filled | a 4.0% gap down opened on 2026-08-04 has been "filled" 13 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 13 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 14.8 percentage points (the stock gained 17.1% while the market gained 2.3%) | +14.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 31.7 percentage points (the stock gained 34.8% while the market gained 3.1%) | +31.7% |
| vs market, 6 months | over the past 6 months this stock beat the market by 17.9 percentage points (the stock gained 28.9% while the market gained 11.1%) | +17.9% |
| vs market, 12 months | over the past 12 months this stock beat the market by 7.1 percentage points (the stock gained 27.6% while the market gained 20.5%) | +7.1% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 18% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 10.5% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +18.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 29% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $15.52 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +28.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% above the average price paid since it last reported on 2026-08-03 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $18.93 — a volume-weighted average of daily closes over 15 sessions, not a true tick-by-tick VWAP. | +5.5% |
Price levels it has turned at before
SIBN last closed at $19.96 on 2026-08-21. Since 2024-08-21 it has turned at 12 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $19.98 | Resistance | 0.1% above the last close | turned there three times · 2025-05-16 to 2025-12-08 |
| $19.41 | Support | 2.8% below the last close | turned there twice · 2025-11-11 to 2026-08-04 |
| $19.05 | Support | 4.5% below the last close | turned there three times · 2025-02-25 to 2025-07-10 |
| $18.21 | Support | 8.8% below the last close | turned there five times · 2025-02-06 to 2026-07-16 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $18.16.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $18.16 and $18.62 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 2 trading days, since 2026-08-20.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Unusually heavy trading volume · Broke out to a new 20-day high · Broke out to a new 20-day high on heavy volume · in a strong, established uptrend (ADX) | Learn: moving average · golden cross · adx · rsi · breakout · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$25.00 range $20.00 – $32.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SIBN
- Consensus EPS estimate-$0.1281 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Intense competition from larger medical device companies with greater resources (Medtronic, Globus Medical, Alphatec), which may develop superior or patented competing products faster than SI-BONE can commercialize","Significant accumulated operating losses ($450.3 million as of end-2025) and continued unprofitability; reliance on capital market access to fund operations","Dependence on a limited number of suppliers and sole-source suppliers for instruments and materials; tariff impacts and supply chain disruptions could affect product availability and gross margins"]
What changed in the latest 10-Q
AI-assisted comparison of SIBN's 10-Q filed 2026-05-11 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-11) references Form 10-K filed February 24, 2026; older filing (2025-11-10) references Form 10-K filed February 25, 2025
- Newer filing states nearly 150,000 procedures performed as of March 31, 2026; older filing states over 130,000 procedures as of September 30, 2025
- Newer filing adds dedicated subsection 'Introduce Solutions Addressing New Markets' detailing breakthrough device designations and R&D spending ($4.2 million for Q1 2026 vs $4.5 million for Q1 2025)
- Newer filing includes new subsection 'Engage and Educate Physicians' with details on training programs, cadaveric sessions, simulator-based training, and physician re-engagement initiatives
- Newer filing adds new subsection 'Enhance Employee Experience and Engagement' discussing compensation, retention, feedback mechanisms, manager training, and career development check-ins
- Newer filing reports U.S. commercial organization as of March 31, 2026: 89 territory sales managers, 80 clinical support specialists, 336 third-party sales agents (vs comparable 2025 figures)
- Newer filing reports international commercial organization as of March 31, 2026: 10 direct sales representatives and 28 third-party sales agents and resellers
- Newer filing states trailing twelve month average revenue per territory sales manager increased to approximately $2.2 million from $2.0 million as of March 31, 2025
- Removed:
- Older filing's 'Expand Access to Solutions' subsection removed entirely; replaced with different structure in newer filing
- Older filing's 'Physician Engagement' subsection removed; content redistributed in newer filing
- Older filing's 'Expand Addressable Markets' subsection removed
- Older filing's reference to specific product launch dates (iFuse 2009, iFuse-3D 2017, iFuse TORQ 2021, iFuse Bedrock Granite 2022, iFuse INTRA and iFuse TORQ TNT 2024) not included in newer filing overview
- Older filing's detailed product clearance information (U.S. and Europe applications) not included in newer filing
- Older filing's target physician numbers (over 12,000 U.S. physicians, 8,000+ orthopedic/neurological spine surgeons, 4,500 interventional spine physicians) removed from newer filing
- Older filing's academic training program statistics (over 300 programs, approximately 2,100 residents and fellows trained) removed from newer filing
- Reworded:
- Newer filing characterizes company as 'leader in developing and commercializing differentiated solutions targeting surgical and interventional procedures for patients with compromised bone'; older filing described as 'medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy'
- Newer filing emphasizes 'anatomy-specific solutions grounded in biomechanical design expertise and backed by strong clinical evidence'; older filing emphasized 'proprietary minimally invasive surgical implant systems'
- Newer filing reorganized Key Performance Indicators into five distinct subsections with expanded discussion; older filing presented in different order and structure
- Newer filing states over 33% of U.S. sacroiliac joint procedures performed in ASC/OBL settings; older filing states over 30 percent
- Newer filing uses term 'Engage and Educate Physicians' as section header; older filing used 'Physician Engagement'
- Newer filing describes training as 'hands-on cadaveric sessions, simulator-based training, and structured onboarding programs'; older filing mentioned 'combination of hands-on cadaveric and dry-lab training, as well as SI-BONE SImulator'
- Notes:
- Older filing text appears truncated at end ('Expand Addressable Markets' and 'Components of Results of O' sections incomplete); comparison limited to available text
- Different reporting periods (March 31, 2026 vs September 30, 2025) make some personnel and procedure count comparisons not directly comparable
- Restructuring of MD&A sections makes it difficult to determine if content was removed or merely reorganized
Risk Factors
- Added:
- Reference to 'the impact of enacted or proposed tariffs' (newer filing, 2026-05-11) vs. 'proposed tariffs' (older filing, 2025-11-10)
- Statement about 'our ability to attract and retain key personnel and other employees, including those with specialized skills and experience' (newer filing, 2026-05-11) as a consolidated bullet point
- Reference to 'our Annual Report on Form 10-K for the year ended December 31, 2025' (newer filing, 2026-05-11)
- Removed:
- Separate bullet point 'our expectations regarding our ability to retain and recruit key personnel' (older filing, 2025-11-10)
- Separate bullet point 'our ability to attract and retain employees, including those with specialized skills and experience' (older filing, 2025-11-10)
- Reference to 'our Annual Report on Form 10-K for the year ended December 31, 2024' (older filing, 2025-11-10)
- Phrase 'except as may be required by law' at end of forward-looking statements disclaimer (older filing, 2025-11-10)
- Reworded:
- Changed 'sacropelvic anatomy' (older filing, 2025-11-10) to 'spinopelvic anatomy' (newer filing, 2026-05-11)
- Changed 'proposed tariffs' (older filing, 2025-11-10) to 'enacted or proposed tariffs' (newer filing, 2026-05-11)
- Notes:
- The financial statements section shown is truncated in both versions, limiting full comparison of that portion
- Page numbering differs between filings (Item 1A at page 30 in newer vs. page 36 in older), reflecting content reorganization
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 9 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 1 sell ($369214) — 1 selling insider
- Last 90 days0 buys · 9 sells ($635908) — 4 selling insiders
- Last 180 days0 buys · 24 sells ($1M) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-03. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about SIBN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding SIBN as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 5,260,567
- Reported value $66,440,964
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
SIBN had 5,080,650 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
SIBN had 11.3% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 10.9 days to cover at the same settlement.
- Reported short interest (shares) 5,080,650
- Short interest (% of shares outstanding) 11.3%
- Prior settlement (shares) 5,507,086
- Reported change -7.74%
- Days to cover (reported) 10.9
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Medtronic plc
- Globus Medical, Inc.
- Alphatec Holding Inc.
- Aurora Spine Corporation
- Tenon Medical, Inc.
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare SIBN vs…
SI BONE INC is found in…
Frequently asked questions
What does SI BONE INC (SIBN) do?
SI-BONE designs, manufactures, and commercializes implantable devices and surgical instruments for sacroiliac joint fusion procedures. The company's portfolio addresses disorders of the spinopelvic anatomy, with the sacroiliac joint being a primary focus. SI-BONE markets its products to orthopedic surgeons and neurosurgeons, working to establish physician adoption and secure reimbursement from third-party payors.
What sector is SI BONE INC (SIBN) in?
SI BONE INC (SIBN) is classified in the Health Care sector. Its industry is Orthopedic implants and devices. It trades on NASDAQ.
Who are SI BONE INC's (SIBN) competitors?
Notable peers of SI BONE INC (SIBN) include Medtronic plc, Globus Medical, Inc., Alphatec Holding Inc., Aurora Spine Corporation and Tenon Medical, Inc.. This peer set is informational only — not financial advice.
Is SI BONE INC (SIBN) overbought or oversold right now?
SI BONE INC (SIBN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 68, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SIBN come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.